UBC® Rapid

Bladder Cancer detection.

IDL Biotech’s UBC® Rapid is a powerful Doctors-office test (Point-of-Care) for aid in diagnosis and monitoring of bladder cancer.

UBC® Rapid

UBC® Rapid is a powerful Doctors-office test (Point-of-Care) to aid in diagnosing and monitoring bladder cancer patients in conjunction with standard diagnostic procedures. The test measures soluble fragments of cytokeratin 8 and 18 in urine samples. It can easily be performed by a nurse or a technician with minimal training and the results are obtained within 10 minutes. Elevated amounts of cytokeratin protein fragments are present in the urine of individuals with bladder cancer, even at the early stages of the disease.

UBC® Rapid shall be used for quantitative determination in combination with the POC-reader or concile® Ω100.

– The only quantitative POC test platform for urine-based detection of bladder cancer.
– Easy and rapid to perform – result within 10 minutes
– Works with haematuria

IDL Biotech is the legal manufacturer of UBC® Rapid.

Ubc Rapid by arocell

Most eukaryotic cells have cytoplasmic cytoskeletal structures known as intermediate filaments. The cytoskeletal network is responsible for the mechanical integrity of the cell, and it is critical during cellular processes like cell division, motility and cell to cell contacts. At present more than 20 different cytokeratins have been identified, of which cytokeratin 8, 18, and 19 are the most abundant in simple epithelial cells. The cytokeratins are epithelial cell-specific and the cytokeratin pattern is usually preserved during the transformation of normal cells into malignant cells.

Cytokeratins in cancer

Cancer affects everyone – the young and old, the rich and poor, men, women, and children – and represents a tremendous burden on patients, families, and societies. Cancer is one of the leading causes of death in the world.
Normal cells are constantly dividing, but in cancer, abnormal cell growth occurs. This causes the protein cytokeratin to leak out which can be measured with efficient diagnostic tools. Thanks to modern technology, AroCell can quickly diagnose several kinds of cancer non-invasive and pain-freely.

Find more information

UBC® Rapid is a powerful diagnostic parameter in aid of diagnosis and follow-up of bladder cancer, especially for papillary non-invasive high-grade tumors and carcinoma in situ (CIS).

Clinical evaluation

UBC® Rapid performs better than urine cytology in many patients due to improved sensitivity and the combination of UBC® Rapid and cytology enables detection of additional tumors as opposed to cytology alone.

References for UBC® Rapid

1. Giannopoulus A., et al. Comparative evaluation of the diagnostic performance of the BTA Stat test,NMP22 and Urinary Bladder Cancer antigen for primary and recurrent bladder tumors. J Urol 2001; 166:470-475.

2. Lüdecke G., et al. Comparative analysis of sensitivity to blood in the urine for urine-based point-of-care assays (UBC® Rapid, NMP22 BladderChek and BTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on the result of urine-based POC tests. Anticancer Res 2012; 32:2015-2018.

3. Ritter R., et al. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. Urol Oncol 2014; 32:337-344.

4. Ecke T., et al. Preliminary results of a multicentre-study of the UBC® Rapid for detection of urinary bladder cancer. Anticancer Res 2015; 35:2651-2656.

5. Styrke J., et al. Evaluation of the diagnostic accuracy of UBC® Rapid in bladder cancer: a Swedish multicentre study. Scand J Urol 2017; 51:293-300.

6. Ecke T., et al. UBC® Rapid Test for detection of carcinoma in situ (CIS) in urinary bladder cancer. Tumor Biol 2017; 39:1-7.

7. Pichler R., et al. Urinary Rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: Results from a prospective single-center study. Int J Med Sci 2017; 14:811-819.

8. Gleichenhagen J., et al. Evaluation of a new Survivin ELISA and UBC® Rapid for the detection of bladder cancer in urine. Int J Mol Sci 2018; 19:226-239

9. Ecke T., et al. UBC® Rapid Test-A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study. Int J Mol Sci. 2018 Dec 2;19(12)


Diagnostics for oncology

Cancer is one of the leading causes of death worldwide, despite advancing knowledge. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data.


An effective typhoid test

Typhoid fever is water and food-borne infectious disease caused by the bacterium, Salmonella enterica. IDL Biotechs product TUBEX® TF, is a rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever.


We are listed on NASDAQ First North Growth Market.

We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. AroCell is unique for a company of this size.